Here comes another parade of OTCs

The approval for tovorafenib (Ojemda) was based on data from the phase 2 FIREFLY-1 trial, in which the therapy demonstrated an overall repose rate of 67%.

Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.

Check out important updates from the FDA for the week of April 15.

This approval is the second biosimilar approval for manufacturer Alvotech.

The company’s investigational ABCWY vaccine candidate will be reviewed by the FDA by February 14, 2025.

Test your pharmacy news knowledge with our weekly quiz.